| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
15,361 |
14,894 |
$975K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
5,320 |
5,171 |
$485K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,804 |
1,765 |
$136K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
584 |
577 |
$46K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,799 |
1,763 |
$43K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,054 |
1,039 |
$37K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
393 |
381 |
$21K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
348 |
336 |
$12K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
349 |
336 |
$12K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
729 |
718 |
$12K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
139 |
136 |
$10K |
| 81514 |
|
32 |
30 |
$8K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
49 |
49 |
$7K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
79 |
75 |
$7K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
140 |
136 |
$7K |
| 71046 |
Radiologic examination, chest; 2 views |
246 |
238 |
$6K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
39 |
39 |
$6K |
| 87481 |
|
108 |
104 |
$4K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
100 |
96 |
$4K |
| 99215 |
Prolong outpt/office vis |
31 |
31 |
$3K |
| 36415 |
Collection of venous blood by venipuncture |
772 |
758 |
$3K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
25 |
25 |
$3K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
377 |
367 |
$3K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
85 |
82 |
$3K |
| 81001 |
|
659 |
644 |
$2K |
| 80047 |
|
150 |
149 |
$2K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
244 |
238 |
$2K |
| 81025 |
|
144 |
138 |
$1K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
49 |
48 |
$464.14 |
| 87186 |
|
42 |
40 |
$363.38 |
| 87210 |
|
53 |
52 |
$317.11 |
| 93000 |
|
15 |
15 |
$161.28 |
| 81003 |
|
62 |
60 |
$135.23 |